Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, Denis Soulières, Raymond S. McDermott, Jens Bedke, Sophie Tartas, B. Yа. Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemysław Langiewicz, Lori Wood, Hans J. Hammers, Cynthia G. Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles